Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Clofarabine in Refractory Solid Tumors, Lymphomas, or MDS
NCT02211755Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2014
- Primary completion
- Aug 2025
- Modality
- Modified Peptides, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bortezomib and clofarabine in solid tumor, lymphoma and myelodysplastic syndrome (MDS), sponsored by National Cancer Institute. Primary endpoint: Safety and Maximum Tolerated Dose at 21 days. Started Oct 2014; status: completed.
02
Drugs
bortezomibclofarabine
03
Conditions
solid tumorlymphomamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02211755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211755.